QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...

The drug in question, dubbed QLS‑111, has been created with Qlaris’ ATP-sensitive potassium channel modulator platform and is designed to lower intraocular pressure (IOP). The results ...

QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company ...

QLS-31905 is under clinical development by Qilu Pharmaceutical and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition ...

QLS-111 is under clinical development by Qlaris Bio and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase II drugs for Open-Angle Glaucoma have a 39% phase transition ...